BMS Reports P-III Trial (CheckMate-274) Results of Opdivo (nivolumab) for High-Risk Muscle-Invasive Urothelial Carcinoma
Shots:
- The 3yr. follow-up results from the P-III trial (CheckMate-274) evaluating Opdivo (240mg, q2w for ~1yr.) vs PBO in a ratio (1:1) in 709 patients with MIUC who are at a high risk of recurrence after radical resection
- The results showed a sustained clinical benefit. Across all randomized patients, m-DFS/m-NUTRFS/m-DMFS/m-PFS2 was (22.0 vs 10.9mos. with 29% risk reduction)/ (25.9 vs 13.7mos.)/ (47.1 vs 28.7mos.)/ (61.2 vs 47.1mos.)
- Patients whose tumor cells express PD-L1 ≥1%, m-DFS/m-NUTRFS/ m-DMFS/ m-PFS2 was (52.6 vs 8.4mos. with a 48% reduction in risk of disease recurrence or death)/ (52.6 vs 8.4mos.)/ (not reached vs 20.7mos.)/ (not reached vs 39.4mos.), grade 3-4 TRAEs (18.2% vs 7.2%) & was consistent with the primary analysis
Ref: BMS | Image: BMS
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
